Tokyo Tape
Sign in
← Santen Pharmaceutical

Annual report

4536.TEDINET S100R54I
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 156
MetricValuePeriodScopeSource row
Revenue¥279.0bn2022-04-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥266.3bn2021-04-01 → 2022-03-31Cons.Revenue IFRS
Revenue¥249.6bn2020-04-01 → 2021-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥241.6bn2019-04-01 → 2020-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥234.0bn2018-04-01 → 2019-03-31dCons.Revenue IFRS (5-year summary)
Operating income−¥3.1bn2022-04-01 → 2023-03-31Cons.Operating profit loss IFRS
Operating income¥35.9bn2021-04-01 → 2022-03-31Cons.Operating profit loss IFRS
Profit before tax−¥5.8bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥35.6bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS
Profit before tax¥11.7bn2020-04-01 → 2021-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥32.1bn2019-04-01 → 2020-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥43.1bn2018-04-01 → 2019-03-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)−¥14.9bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥27.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥9.3bn2020-04-01 → 2021-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥23.6bn2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥32.0bn2018-04-01 → 2019-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income−¥15.0bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS
Net income¥27.2bn2021-04-01 → 2022-03-31Cons.Profit loss IFRS
Total assets¥421.2bnat 2023-03-31Cons.Assets IFRS
Total assets¥460.0bnat 2022-03-31Cons.Assets IFRS
Total assets¥405.3bnat 2021-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥408.8bnat 2020-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥391.2bnat 2019-03-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥127.9bnat 2023-03-31Cons.Liabilities IFRS
Total liabilities¥123.1bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥293.3bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥336.8bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥309.6bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥294.0bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥337.5bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥310.2bnat 2021-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥302.9bnat 2020-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥290.9bnat 2019-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥57.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥83.0bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥62.9bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥91.4bnat 2020-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥70.8bnat 2019-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥37.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥46.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥38.8bn2020-04-01 → 2021-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥39.9bn2019-04-01 → 2020-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥32.9bn2018-04-01 → 2019-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥26.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥35.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥53.4bn2020-04-01 → 2021-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥5.2bn2019-04-01 → 2020-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.9bn2018-04-01 → 2019-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥37.2bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥5.6bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥16.7bn2020-04-01 → 2021-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥12.7bn2019-04-01 → 2020-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥28.1bn2018-04-01 → 2019-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥-38.62022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥68.072021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.32020-04-01 → 2021-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥59.162019-04-01 → 2020-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥78.672018-04-01 → 2019-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-38.62022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.972021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.262020-04-01 → 2021-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥59.012019-04-01 → 2020-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥78.432018-04-01 → 2019-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥783.3at 2023-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥843.6at 2022-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥776.16at 2021-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥758.5at 2020-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥728.97at 2019-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio69.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio73.4%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio76.5%at 2021-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.1%at 2020-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.4%at 2019-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE-4.7%2022-04-01 → 2023-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.4%2021-04-01 → 2022-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE3.0%2020-04-01 → 2021-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE8.0%2019-04-01 → 2020-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE11.1%2018-04-01 → 2019-03-31dCons.Rate of return on equity IFRS (5-year summary)
Employees4,144at 2023-03-31Cons.Number of employees
Employees4,318at 2022-03-31Cons.Number of employees
Employees4,232at 2021-03-31dCons.Number of employees
Employees4,111at 2020-03-31dCons.Number of employees
Employees4,076at 2019-03-31dCons.Number of employees
Revenue¥196.6bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥190.8bn2021-04-01 → 2022-03-31StandaloneNet sales
Revenue¥186.1bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥182.6bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Revenue¥176.2bn2018-04-01 → 2019-03-31dStandaloneNet sales (5-year summary)
Operating income¥24.8bn2022-04-01 → 2023-03-31StandaloneOperating income
Operating income¥21.4bn2021-04-01 → 2022-03-31StandaloneOperating income
Ordinary income¥27.1bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥22.5bn2021-04-01 → 2022-03-31StandaloneOrdinary income
Ordinary income¥25.3bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥34.9bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥33.2bn2018-04-01 → 2019-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥49.9bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Profit before tax¥25.2bn2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Net income−¥59.4bn2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥17.4bn2021-04-01 → 2022-03-31StandaloneProfit loss
Net income¥21.8bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥27.4bn2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Net income¥28.0bn2018-04-01 → 2019-03-31dStandaloneNet income loss (5-year summary)
Total assets¥282.9bnat 2023-03-31StandaloneAssets
Total assets¥363.8bnat 2022-03-31StandaloneAssets
Total assets¥353.6bnat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥340.0bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total assets¥321.9bnat 2019-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥83.6bnat 2023-03-31StandaloneLiabilities
Total liabilities¥66.3bnat 2022-03-31StandaloneLiabilities
Net assets / equity¥199.3bnat 2023-03-31StandaloneNet assets
Net assets / equity¥297.5bnat 2022-03-31StandaloneNet assets
Net assets / equity¥294.2bnat 2021-03-31dStandaloneNet assets
Net assets / equity¥283.5bnat 2020-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥265.4bnat 2019-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥23.8bnat 2023-03-31StandaloneCash and deposits
Cash and deposits¥37.6bnat 2022-03-31StandaloneCash and deposits
EPS (basic)¥-153.182022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥43.592021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥54.442020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥68.632019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥68.962018-04-01 → 2019-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥43.532021-04-01 → 2022-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥54.332020-04-01 → 2021-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥68.462019-04-01 → 2020-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥68.762018-04-01 → 2019-03-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥322022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥322021-04-01 → 2022-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥282020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥272019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥262018-04-01 → 2019-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥529.72at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥742.3at 2022-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥734.61at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥708.12at 2020-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥662.95at 2019-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio70.3%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio81.7%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio83.1%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio83.2%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.2%at 2019-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE-23.9%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE5.9%2021-04-01 → 2022-03-31StandaloneRate of return on equity (5-year summary)
ROE7.5%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE10.0%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
ROE10.6%2018-04-01 → 2019-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued375,886,000at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued400,695,000at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued400,369,000at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued400,028,000at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued399,782,000at 2019-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees1,807at 2023-03-31StandaloneNumber of employees
Employees1,842at 2022-03-31StandaloneNumber of employees
Employees1,875at 2021-03-31dStandaloneNumber of employees
Employees1,843at 2020-03-31dStandaloneNumber of employees
Employees1,815at 2019-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 1,665
ItemContextValueUnit
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember-98245000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_TreasuryStockMember-364000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember190915000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember8015000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember8015000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember331000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember199261000000JPY
Salaries and allowances sgaPrior1YearDuration_NonConsolidatedMember8122000000JPY
Salaries and allowances sgaCurrentYearDuration_NonConsolidatedMember8463000000JPY
Provision for bonuses sgaPrior1YearDuration_NonConsolidatedMember1913000000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember1174000000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember799000000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember856000000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember6658000000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember7051000000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember31350000000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember29679000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-06-27
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第111期（自　2022年４月１日　至　2023年３月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)参天製薬株式会社
Company name in english cover pageFilingDateInstantSANTEN PHARMACEUTICAL CO., LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長兼CEO　伊藤　毅
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)大阪府大阪市北区大深町４番20号
Telephone number address of registered headquarter cover pageFilingDateInstant06(4802)9322
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)Manager, Group Accounting高木　宏典
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)大阪府大阪市北区大深町４番20号
Telephone number nearest place of contact cover pageFilingDateInstant06(4802)9322
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)Manager, Group Accounting高木　宏典
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00949
Fund codeFilingDateInstant－
Security codeFilingDateInstant45360
Filer name in japaneseFilingDateInstant
Original text (Japanese)参天製薬株式会社
Filer name in englishFilingDateInstantSANTEN PHARMACEUTICAL CO., LTD.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantIFRS
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Current fiscal year start dateFilingDateInstant2022-04-01
Current period end dateFilingDateInstant2023-03-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2023-03-31
Previous fiscal year start dateFilingDateInstant2021-04-01

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identitynon_consolidated 2022-03-31pass
balance sheet identitynon_consolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2021-04-01/2022-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass